Study design
It was an investigator-initiated prospective, individually randomized, open-label, single-center trial to evaluate the efficacy and safety of oral nelfinavir in adults (aged ≥ 18 years) with mild or moderate COVID-19. The study was carried out at Shanghai Public Health Clinical Center in Shanghai, China. The ethics committee of Shanghai Public Health Clinical Center granted ethical approval on Jun 2, 2020. This clinical trial was done according to the principles of the 